Tesofensine Phase III

What It Is

Tesofensine (NS2330) is a centrally acting, orally bioavailable small-molecule drug — not a peptide. Chemically it is a phenyltropane derivative, structurally related to cocaine and to other dopamine-active tropanes, but pharmacologically dissimilar in that its onset is slow and its half-life is extraordinarily long (approximately 220 hours, or roughly 9 days). It functions as a triple monoamine reuptake inhibitor (SMRI), simultaneously blocking the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT), thereby raising synaptic concentrations of all three neurotransmitters in the central nervous system.

Tesofensine was originally synthesized and developed by the Danish biotechnology company NeuroSearch, in collaboration with Boehringer Ingelheim, beginning in the late 1990s. Its first clinical destinations were neurodegenerative — Phase 2 trials in Alzheimer's disease and Parkinson's disease ran in the early 2000s. Those programs were not successful: tesofensine did not meet the predefined efficacy thresholds for either indication. Boehringer Ingelheim returned the rights to NeuroSearch in 2009. What clinicians did notice consistently in those neurology trials was an unintended, dose-dependent loss of body weight in overweight and obese participants, which in some cohorts approached double-digit percentages. That observation pivoted the molecule toward obesity development.

The pivotal anti-obesity result came from the TIPO-1 Phase 2b trial published in The Lancet in 2008 by Astrup and colleagues (PMID 18950853). After 24 weeks, mean weight loss was 4.5%, 9.2%, and 10.6% with tesofensine 0.25 mg, 0.5 mg, and 1.0 mg respectively, all on top of an energy-restricted diet, compared with 2.0% on diet plus placebo. That magnitude — roughly twice that of any anti-obesity agent FDA-approved at the time — generated substantial pharmaceutical and lay-press attention. NeuroSearch subsequently licensed and then sold the program; the program is now owned and run by Saniona, which acquired the rights in 2014. As of April 2026, tesofensine has not received FDA approval for any indication, and the company has voluntarily paused its lead Phase 2b programs in hypothalamic obesity and Prader-Willi syndrome citing funding limitations rather than safety or efficacy concerns.

One commonly cited fact about tesofensine — that it is "approved as Tesomet in Mexico" — is overstated. Tesomet is a fixed-dose combination of tesofensine and the beta-1 selective blocker metoprolol, designed to mitigate tesofensine's tachycardic and pressor effects; it is investigational worldwide and has not been granted full marketing authorization by any major regulator. Tesofensine has surfaced increasingly in the optimization community in 2024–2026 because of GLP-1 drug shortages, the rise of body-recomposition discourse, and the migration of attention from off-label semaglutide to non-incretin appetite-suppressant alternatives. None of that off-label discourse should be read as approval. Tesofensine is an investigational small molecule, and informed users should treat it as one.

Mechanism of Action

Tesofensine is mechanistically a small-molecule reuptake inhibitor at the level of the synaptic cleft, with downstream effects that reach far into hypothalamic appetite circuits, mesolimbic reward, and cortical-frontal control. It does not bind the GLP-1 receptor, the GIP receptor, leptin receptors, or any of the gut-hormone targets that define the current generation of anti-obesity peptides. The mechanism is fundamentally different from semaglutide, tirzepatide, retatrutide, liraglutide, and cagrilintide, and that mechanistic distinction is most of what matters for understanding the drug.

• Triple monoamine transporter blockade (DAT/NET/SERT) — Tesofensine is a potent inhibitor of all three transporters. Originally reported IC50 values were approximately 8 nM (DAT), 3 nM (NET), and 11 nM (SERT). More recent submissions revised these to NET 1.7 nM, SERT 11 nM, DAT 65 nM — meaning the noradrenergic and serotonergic effects predominate at clinically relevant doses, with dopaminergic activity being modest. This revised pharmacology is the most parsimonious explanation for why tesofensine failed to reverse Parkinson's symptoms (insufficient DAT inhibition) yet performs robustly in obesity (where NET-driven sympathetic tone, satiety, and energy expenditure are central).
• α1-adrenoceptor pathway dominates appetite suppression — Axel et al. (2010, Neuropsychopharmacology) showed in diet-induced obese rats that tesofensine's hypophagic effect was almost completely reversed by co-administration of prazosin (α1-adrenoceptor antagonist), and partially reversed by SCH23390 (D1 antagonist). Translation: the appetite-suppressant effect runs primarily through indirect stimulation of central α1-adrenoceptors with a contributing dopamine D1 component, both downstream of NET/DAT blockade. This mechanism is closer to sibutramine than to phentermine.
• Striatal DAT occupancy in humans — Appel et al. (2014, Eur Neuropsychopharmacol; PMID 24239329) used [18F]-PE2I PET imaging in healthy volunteers to quantify striatal DAT occupancy across tesofensine doses. At clinically relevant 0.5 mg and 1.0 mg doses, striatal DAT occupancy reached approximately 18–35% — modest by stimulant standards. This sub-saturating DAT occupancy is consistent with the drug's atypically low abuse potential despite triple-monoamine activity (Schoedel et al., 2010).
• Lateral hypothalamic GABAergic neuron silencing — A 2024 paper (PMC11042726, PMID 38656972) demonstrated using DeepLabCut behavioral analysis, ensemble electrophysiological recordings, optogenetic activation, and chemogenetic silencing in obese rats that tesofensine differentially silences GABAergic neurons in the lateral hypothalamus (LH) — a critical feeding center. Crucially, this silencing was greater in obese rats than in lean rats, providing a circuit-level mechanism for tesofensine's outsized effect in obese phenotypes.
• Increased resting energy expenditure and fat oxidation — Sjödin et al. (2010, Int J Obes; PMID 20479765) showed in overweight men that tesofensine modestly increases 24-hour energy expenditure and shifts substrate utilization toward fat oxidation, in addition to its appetite-suppressant effect. Both arms of the energy-balance equation move in the weight-loss direction. The thermogenic component is a meaningful differentiator from GLP-1 agonists, which suppress appetite without raising baseline expenditure.
• Sympathetic activation drives cardiovascular adverse effects — Bentzen et al. (2013, Obesity) demonstrated in rats that tesofensine elevates heart rate and blood pressure via sympathetic activation (downstream of NET inhibition), and that anti-hypertensive treatment with metoprolol preserved appetite suppression while blunting cardiovascular effects. This is the pharmacological rationale for the Tesomet combination.
• Long pharmacokinetic tail — Tesofensine has a half-life of approximately 220 hours (~9 days). It is metabolized primarily by CYP3A4 to a desalkyl metabolite (M1, NS2360) which has its own long half-life (~16 days) and contributes meaningfully to the active drug profile in vivo (Lehr et al., 2008, Br J Pharmacol). This long terminal half-life means steady-state takes weeks, dose changes equilibrate slowly, and discontinuation does not produce rapid washout.
• Slow Tmax — Tesofensine reaches peak plasma concentration approximately 6 hours after oral dosing — atypically slow for a CNS-active monoamine reuptake inhibitor. Combined with sub-saturating striatal DAT occupancy, this slow rise is the core mechanistic reason tesofensine does not function as a recreational stimulant despite its dopaminergic activity (Schoedel et al., 2010, Clin Pharmacol Ther; PMID 20520602).
• BDNF and antidepressant signal — Sustained tesofensine treatment has been reported to increase brain-derived neurotrophic factor (BDNF) levels in animal models, which is the proposed substrate for an emerging antidepressant signal seen in some obese cohorts. The clinical antidepressant signal is preliminary and was not the primary endpoint of any trial.
• What it does not do — Tesofensine does not engage GLP-1, GIP, glucagon, amylin, leptin, or melanocortin receptors directly. It does not delay gastric emptying. It does not enhance insulin secretion. Its mechanism is purely central monoaminergic, with downstream metabolic consequences. This distinction is the single most important framing for users comparing it to GLP-1 agonists.

What the Research Shows

Tesofensine has been studied across three distinct development arcs: neurodegenerative disease (failed), obesity (positive Phase 2, never reached Phase 3), and rare orphan obesities — Prader-Willi syndrome and acquired hypothalamic obesity (Phase 2a positive, Phase 2b paused).

• TIPO-1 obesity trial (Astrup 2008) — The headline result. 203 obese patients (BMI 30–40) randomized to tesofensine 0.25 mg, 0.5 mg, 1.0 mg, or placebo plus diet for 24 weeks. Mean placebo-corrected weight losses were 2.5%, 7.2%, and 8.6% respectively (4.5%, 9.2%, 10.6% absolute on tesofensine vs 2.0% on placebo). This is approximately twice the magnitude of weight loss reported for sibutramine or rimonabant in comparable trials (PMID 18950853).
• TIPO-4 open-label extension — 140 patients who completed TIPO-1 were re-enrolled after a ~3-month wash-out, treated with 0.5 mg tesofensine once daily and allowed up-titration to 1.0 mg. Sustained additional weight loss was reported, consistent with the 24-week TIPO-1 data.
• Energy metabolism (Sjödin 2010) — In overweight and moderately obese men, tesofensine increased 24-hour energy expenditure and fat oxidation rate, in addition to suppressing appetite. The thermogenic component was modest but consistent (PMID 20479765).
• Tesomet for hypothalamic obesity (Huynh 2022, Eur J Endocrinol) — 21 hypopituitary adults with acquired hypothalamic obesity (NCT03845075) randomized 2:1 to Tesomet (0.5 mg tesofensine + 50 mg metoprolol) vs placebo for 24 weeks, then 24-week open-label extension. Mean change in body weight was −7.84 kg with Tesomet vs −0.34 kg placebo (P=0.03). No significant difference in heart rate or blood pressure between groups — the metoprolol component effectively mitigated tesofensine's cardiovascular signal (PMID 35294397).
• Tesomet for Prader-Willi syndrome (Phase 2a, NCT03149445) — Initial 9-adult exploratory study showed clinically meaningful weight loss and substantial reduction in hyperphagia (the defining symptom of PWS) over 3 months. Plasma tesofensine concentrations were 2–4× higher than in obese non-PWS cohorts at the same dose, prompting protocol revision to lower-dose Tesomet for adolescent extension. Adolescent extension reported significant weight, BMI, and hyperphagia reductions. FDA granted Tesomet orphan drug designation for PWS in 2018 and confirmed the 505(b)(2) regulatory pathway is open.
• Phase 2b PWS and hypothalamic obesity trials initiated then paused — Saniona initiated Phase 2b trials in both indications in late 2021 (the PWS trial enrolled randomized 16-week treatment + 36-week open-label extension). Both Phase 2b trials were voluntarily paused in 2022–2023 by Saniona due to funding limitations, not safety or efficacy. As of April 2026, both programs remain paused; Saniona continues to seek partnership or refinancing to resume.
• Failed neurodegenerative arc (Hauser 2007 early PD; Rascol 2008 ADVANS advanced PD; PMID 18474731) — Two well-conducted Phase 2 randomized double-blind placebo-controlled trials in Parkinson's disease. Hauser 2007 (Movement Disorders) tested tesofensine 0.25/0.5/1.0 mg as monotherapy in 261 early-PD patients; the 1.0 mg arm produced a transient UPDRS improvement at week 6 that did not sustain. Rascol 2008 ADVANS tested 0.125/0.25/0.5/1.0 mg as adjunct to levodopa in advanced PD with motor fluctuations; small mean improvements (e.g., −4.7 UPDRS points and −7.1% off time at certain doses) were observed but were not clinically transformative. Boehringer Ingelheim concluded these and one Alzheimer's trial did not meet predefined Phase 3 progression criteria and returned rights to NeuroSearch.
• Cognitive and Alzheimer's signal — minimal — A pharmacokinetic-pharmacodynamic modeling paper (Lehr et al., 2009, AAPS J) and subsequent reviews note a Phase 2a Alzheimer's signal that did not reproduce in Phase 2b. Astrup et al. (Obesity 2008; PMID 18356831) summarized weight loss in PD/AD trial cohorts as the consistent off-target finding that ultimately redirected development.
• Preclinical DIO rat models — Hansen et al. (2010, Eur J Pharmacol) compared tesofensine head-to-head with sibutramine and rimonabant in diet-induced obese rats. Tesofensine produced more sustained weight loss and superior glycemic control improvement than either comparator at allometrically scaled doses. The cafeteria-fed DIO female rat model used in Heal/Smith comparison studies has approximately 95% predictive correlation with human anti-obesity drug efficacy, lending unusually high translational confidence to these preclinical results.
• Abuse potential — confirmed low (Schoedel 2010, Clin Pharmacol Ther) — Single-dose, randomized, double-blind, crossover study in 52 recreational stimulant users compared tesofensine (single doses up to 1.0 mg) against placebo, D-amphetamine 30 mg (positive control), bupropion, and atomoxetine. Tesofensine subjective effects (drug liking, ARCI Amphetamine scale, "any effects" VAS) were not significantly different from placebo and far below D-amphetamine. Conclusion: tesofensine is unlikely to be recreationally abused (PMID 20520602). The slow Tmax, sub-saturating DAT occupancy, and long half-life all explain this finding.

Human Data

Tesofensine has accumulated more high-quality human data than most compounds in this database — it is a small-molecule pharmaceutical asset that has run multiple completed Phase 2 trials with peer-reviewed publications. The contrast with peptides like BPC-157 (3 small pilots) is significant. What it lacks is Phase 3.

• NCT00394667 — Phase 2 obesity trial (TIPO-1 / TIPO-2 / TIPO-4 program). Foundation of the entire obesity development arc. Published as Astrup 2008 Lancet (PMID 18950853).
• NCT03845075 — Phase 2 randomized placebo-controlled trial of Tesomet in 21 adults with acquired hypothalamic obesity. Published as Huynh 2022 Eur J Endocrinol (PMID 35294397). Mean −7.84 kg vs −0.34 kg placebo at 24 weeks.
• NCT03149445 — Phase 2a exploratory Tesomet trial in adults and adolescents with Prader-Willi syndrome. Top-line results indicated meaningful weight loss and hyperphagia reduction; published company press releases (2018 and beyond) summarize.
• Phase 2b PWS trial (paused) — Initiated December 2021. 16-week double-blind + 36-week open-label extension. Voluntarily paused in 2023 for funding.
• Phase 2b hypothalamic obesity trial (paused) — Initiated 2021–2022. Voluntarily paused for funding.
• Parkinson's Phase 2 (Hauser 2007 / Rascol 2008) — 261 early-PD patients (Hauser) and ~140 advanced-PD patients (Rascol ADVANS, PMID 18474731). Negative or marginal efficacy. These trials demonstrated the cardiovascular signal (heart rate elevation, modest BP change) and the weight-loss off-target finding that drove the obesity pivot.
• Alzheimer's Phase 2 — Phase 2a Alzheimer's trial showed cognitive signal that did not reproduce in Phase 2b. Quantitative-pharmacology modeling paper (Lehr 2009, AAPS J) used the trial data to inform predicted Phase 3 outcomes; the Phase 3 outcome was never tested because Boehringer returned rights and the program was discontinued.
• Healthy volunteer abuse-liability study (Schoedel 2010, PMID 20520602) — 52 recreational stimulant users; tesofensine indistinguishable from placebo on subjective drug-effect measures. The drug is therefore unlikely to be scheduled by DEA in any restrictive category if it ever achieves U.S. approval.
• PET DAT occupancy in healthy volunteers (Appel 2014, PMID 24239329) — Quantified striatal dopamine transporter occupancy across the clinical dose range. Sub-saturating occupancy at 0.5–1.0 mg is consistent with both the appetite-suppressant efficacy and the low abuse signal.

What the existing dataset does not address: long-term cardiovascular safety beyond 24 weeks, MACE outcomes, sustainability of weight loss past 1 year, head-to-head against semaglutide/tirzepatide, behavior in adolescents outside PWS, drug-drug interactions with common chronic medications, and outcomes in patients with established cardiovascular disease. None of these have been studied at the scale modern obesity drug regulation requires.

Dosing from the Literature

The following dosing reflects published clinical trial protocols. This is not medical advice. Tesofensine is investigational; no FDA-approved dose exists.

Reconstitution & Storage

Tesofensine is a small-molecule oral drug. Unlike peptides in this database, it is not lyophilized and does not require reconstitution. It is supplied (in research and clinical-trial settings) as oral capsules or tablets at fixed strengths (typically 0.25 mg, 0.5 mg, or 1.0 mg).

• No reconstitution required — Tesofensine is administered orally as the supplied solid dosage form. Do not attempt to reconstitute or inject it.
• Bioavailability — Oral bioavailability is high (~90%) with limited first-pass effect. Food does not appear to materially alter absorption in published PK studies.
• Tmax — Approximately 6 hours post-dose. The slow rise contributes to its low abuse signal.
• Long terminal half-life — Roughly 220 hours for tesofensine and ~16 days for active metabolite NS2360. Plan dose changes with steady-state in mind.

→ Use the Kalios Dosing Calculator for tesofensine titration scheduling

Side Effects & Risks

Tesofensine has the most thoroughly characterized side-effect profile of any non-FDA-approved compound in this database. Across TIPO-1, the Parkinson's trials, and the Tesomet trials, several consistent themes emerge:

• Cardiovascular — the primary concern — At 0.5 mg, mean heart rate increased by approximately 7 bpm above placebo in TIPO-1, with blood pressure largely unchanged. At 1.0 mg, more pronounced HR and modest BP elevations occurred. The Lancet expression of concern (PMID 19249626) and accompanying Tsai letter (PMID 19249625) emphasized that exclusion of psychiatric and cardiovascular-risk patients from TIPO-1 may underestimate real-world cardiovascular adverse events. Tesomet (with metoprolol) substantially mitigates this signal.
• Common dose-dependent side effects — Dry mouth, insomnia, headache, nausea, diarrhea, and constipation. Dry mouth and insomnia were the most clearly dose-responsive. Withdrawal due to adverse events in TIPO-1 was 13% on tesofensine vs 6% on placebo.
• Psychiatric — agitation, mood changes — Significant increases in confusion, vigour and activity, anger, and hostility were measured on the Profile of Mood States (POMS) at 1.0 mg vs placebo, with no significant change in depression, tension, or fatigue. The Tsai letter highlighted concern about agitation, panic attacks, and mood disorders given tesofensine's monoaminergic activity. Real-world prevalence in unselected populations is unknown.
• Abuse potential — low in healthy stimulant-naive and stimulant-experienced users — Schoedel 2010 (PMID 20520602) is reassuring: tesofensine produced subjective drug-effects scores indistinguishable from placebo in 52 recreational stimulant users, and significantly lower than D-amphetamine 30 mg. The slow Tmax and sub-saturating DAT occupancy are the mechanistic explanation.
• Long half-life is a double-edged sword — A ~9-day half-life (~16 days for the active metabolite) means dose changes equilibrate over weeks, side effects accumulate slowly, and discontinuation does not produce rapid washout. Adverse events that emerge after weeks of dosing are difficult to attribute and slow to resolve. This pharmacokinetic profile is uncommon in obesity therapeutics.
• Drug-drug interactions — CYP3A4 — Tesofensine is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (azole antifungals, certain macrolides, grapefruit) may increase exposure; strong inducers (rifampicin, carbamazepine) may decrease it. Co-administration with serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, dextromethorphan) raises serotonin syndrome concern given tesofensine's SERT activity. Concurrent stimulants (amphetamines, methylphenidate, sympathomimetic decongestants) compound cardiovascular and psychiatric risk.
• Contraindications — uncharacterized but inferable — Pre-existing arrhythmia, uncontrolled hypertension, ischemic heart disease, history of stroke, anxiety disorders, bipolar disorder, history of substance use disorder, pregnancy, breastfeeding, and pediatric use (outside the PWS adolescent program) are the conservative contraindications. None has been formally adjudicated by an FDA label because no FDA label exists.
• WADA status — Tesofensine is not specifically named on the WADA Prohibited List. However, as a stimulant-class agent that elevates synaptic dopamine, norepinephrine, and serotonin, it would plausibly be evaluated under S6 (stimulants) if used in-competition by a tested athlete. Athletes subject to anti-doping testing should not use tesofensine without explicit federation guidance.
• Sourcing risk — Tesofensine sold through online research-chemical channels is unverified. Independent COA testing for a small molecule (HPLC, mass spec) is the practical floor for purity assurance. Counterfeit material has appeared in multiple international markets in 2024–2025.

Supportive Nutrition & Supplements

Tesofensine is an appetite-suppressant and mild thermogenic. The risk profile of using it without nutritional structure is that intake drops rapidly and broadly — including protein and micronutrients — leading to lean-mass loss, micronutrient depletion, and fatigue. The supportive nutritional approach below is generic to any pharmacological appetite suppressant and is not tesofensine-specific research.

• Protein floor — At least 1.6 g/kg bodyweight/day (and ideally 2.0 g/kg for actively training individuals) during weight-loss. With suppressed appetite, this almost always requires deliberate protein-first meal construction or whey/casein supplementation. Failure to hit protein floor is the single most common reason for excess lean-mass loss on appetite-suppressant therapy.
• Resistance training — Non-negotiable for body-recomposition outcomes on appetite suppressants. 3–4 sessions/week of progressive resistance training preserves the lean-mass that monoaminergic suppressants would otherwise erode.
• Multivitamin + minerals — A high-quality once-daily multi covers the routine deficiencies that emerge when total intake drops (B-complex, iron, zinc, magnesium, selenium, iodine, vitamin D, vitamin K2). Specifically check vitamin D (target 40–60 ng/mL), B12, ferritin, and magnesium with ongoing labs.
• Electrolytes — Tesofensine has mild diuretic-like sympathetic effects. Sodium 2–3 g/day during the day plus modest potassium and magnesium prevents the orthostatic dizziness and headaches that commonly accompany rapid weight loss.
• Hydration — Dry mouth is the most common dose-dependent side effect. Higher-than-baseline water intake (35–40 mL/kg/day) plus sugar-free chewing gum or xylitol mints help symptomatic management.
• Sleep hygiene — Insomnia is the second most-common dose-dependent side effect. Dose in the morning rather than the evening; avoid afternoon caffeine; restrict blue light in the evening; consider magnesium glycinate at bedtime.
• Avoid additional stimulants — Stacking tesofensine with caffeine >300 mg/day, ephedra, yohimbine, synephrine, or any sympathomimetic compounds the cardiovascular and anxiety risk and is the most common avoidable adverse-event amplifier.
• Avoid serotonergic supplements — 5-HTP, tryptophan supplements, SAM-e, and St. John's wort are theoretical serotonin-syndrome additives given tesofensine's SERT inhibition.
• Fiber — 25–35 g/day mitigates both the constipation and dry mouth and supports satiety on a smaller-volume diet.
• Omega-3 — 2 g EPA+DHA daily supports mood stability and may modestly offset the mood reshaping seen at higher doses in TIPO-1.

What to Expect — Timeline

The following is not a clinical prognosis. It is a synthesis of TIPO-1, TIPO-4, and Tesomet trial trajectories combined with consistent themes from the user-reports community. Individual response varies. Tesofensine has a long pharmacokinetic tail, so changes appear and disappear slowly.

• Day 1–7 (initial) — Mild appetite suppression, often subtle initially. Dry mouth almost universal. Some users report transient mild nausea or headache. Insomnia begins to manifest at higher doses; morning dosing is the standard mitigation. Heart rate may begin a measurable upward shift.
• Week 2–4 (titration / accumulation) — Plasma drug accumulating toward steady-state. Appetite suppression deepens and stabilizes. Initial weight loss appears, often weighted toward water/glycogen in the first 1–2 weeks, then transitioning to fat mass. Heart rate plateau at ~+5–10 bpm above baseline at 0.5 mg.
• Week 5–8 (steady-state) — Effects fully expressed. Most users at 0.5 mg report durable reduction in food preoccupation and reduced portion sizes. Body weight typically declines at a rate of ~0.5–1.0 kg/week in responders; faster in higher-BMI starters, slower in lower-BMI starters.
• Week 8–24 (maintenance) — TIPO-1 trajectory: continued near-linear weight loss through 24 weeks at 0.5 mg, with the absolute weight-loss approaching ~9–10% of baseline. Plateau is uncommon within this window, distinguishing tesofensine's trajectory from many other suppressants. Cardiovascular adaptation: HR remains modestly elevated; clinically significant BP shifts are uncommon at 0.5 mg.
• Beyond 24 weeks — TIPO-4 open-label data suggest continued weight loss for at least an additional 24 weeks. Long-term durability beyond a year has not been characterized in published trials. The mechanism does not predict tachyphylaxis, but evidence is absent.
• Discontinuation — Slow due to the long half-life. Plasma drug detectable for weeks after the last dose. Appetite re-emerges gradually; weight regain trajectory is highly individual and depends heavily on whether sustainable habit changes were established during treatment.
• Non-responders — A minority of obese patients in TIPO-1 had minimal weight loss despite adequate dosing. Mechanism is unclear; some authors hypothesize CYP3A4-mediated low exposure (relevant to drug-drug interactions and fast-metabolizer pharmacogenomics) or insufficient α1-adrenergic responsiveness.
• Red flags to stop — Sustained resting HR >100 bpm, palpitations, chest pain, severe insomnia, panic attacks, new-onset hypertension, mood disturbance, or any psychiatric symptom that is escalating. Do not "push through" cardiovascular signals; they are the dose-limiting toxicity.

Quick Compare — Tesofensine vs Semaglutide vs Tirzepatide vs Phentermine

The most common comparison questions for tesofensine in 2026 come from users contrasting it with GLP-1 agonists (semaglutide, tirzepatide) and with classical phentermine. These are mechanistically distinct, dose differently, have very different evidence bases, and carry different side-effect profiles.

Practical interpretation:

• Mechanistic categories don't compete; they fill different lanes — GLP-1 agonists work peripherally and centrally via incretin pathways; tesofensine works exclusively via central monoamines; phentermine works peripherally via sympathetic activation. A user who tolerates one poorly may tolerate the others well, and vice versa.
• Phase 3 evidence asymmetry — Semaglutide and tirzepatide each have multiple completed Phase 3 trials with cardiovascular outcomes data. Tesofensine has none. This is the single largest differentiator.
• Cardiovascular profile differs sharply — Semaglutide is now cardio-protective (SELECT trial). Tesofensine elevates heart rate. Phentermine is contraindicated in cardiovascular disease. This determines who can safely use what.
• Tolerance pattern differs — GI side effects dominate GLP-1 agonist tolerability. CNS side effects (insomnia, mood) dominate tesofensine and phentermine tolerability. This drives patient-by-patient choice when other factors are equal.
• Duration of approved use differs — Phentermine is approved short-term only. GLP-1 agonists are approved chronic. Tesofensine's chronic-use safety remains unknown beyond 48 weeks.
• Stacking is not standard — Combining tesofensine with phentermine (both sympathomimetic) is contraindicated in clinical practice. Combining tesofensine with GLP-1 agonists is theoretically additive but has not been studied; sequential use (one then the other) is the safer pattern.

→ See Semaglutide profile  •  → See Tirzepatide profile  •  → See Cagrilintide profile

Practical User Notes

• Morning dosing — Take the daily dose in the morning. Insomnia is the second-most-common side effect; evening dosing reliably worsens it.
• Start low, hold long — Most informed users start at 0.25 mg for at least 4 weeks before any titration. Half-life of ~9 days means equilibrium takes weeks; faster titration is unnecessary and amplifies adverse events.
• Cardiovascular baseline first — Resting HR, BP, and ideally a 12-lead ECG before initiating. Daily home HR/BP for the first month. Tesofensine without baseline cardiovascular data is the single most common avoidable safety failure.
• Beta-blocker co-administration is the trial-grade approach — Tesomet (with metoprolol) is investigational specifically because it mitigates HR and BP elevation. Users with even modest cardiovascular signal should consult their physician about a low-dose beta-blocker (the trials use 50 mg metoprolol succinate).
• Avoid all stimulant stacking — Caffeine >300 mg/day, yohimbine, synephrine, ephedra, ADHD stimulants, decongestants. These compound the cardiovascular and anxiety profile multiplicatively. The community failure mode is "tesofensine + pre-workout + nicotine + caffeine" — reliably produces palpitations and panic.
• Avoid serotonergic stacking — SSRIs, SNRIs, MAOIs, tramadol, dextromethorphan, 5-HTP, tryptophan, St. John's wort. Tesofensine inhibits SERT; combining with other serotonergic agents creates serotonin-syndrome risk. Discuss any psychiatric medication stack with the prescribing physician before adding tesofensine.
• Mind the 5-HTP, kratom, MDMA pitfalls — Common community combinations that should not be done concurrently with tesofensine.
• Eat protein deliberately — Appetite suppression is broad and indiscriminate. Without intentional protein-first meal construction, lean mass loss is the silent failure mode. 1.6–2.0 g/kg is the floor.
• Resistance train — Three to four sessions per week. The body-composition outcomes on tesofensine are vastly better with resistance training than without.
• Hydrate aggressively — Dry mouth is universal. Drink to thirst and beyond; sugar-free electrolytes during the day.
• Track mood — Anyone with a history of anxiety, panic, depression, bipolar, or psychotic spectrum should be monitored formally. A simple weekly PHQ-9 or POMS check during the first 12 weeks is reasonable risk-management.
• Plan for slow discontinuation — The long half-life means tesofensine is in your system for weeks after the last dose. Adverse effects don't resolve on day 2 of cessation; they decay slowly. Plan accordingly.
• Do not co-administer with phentermine — Both are central sympathomimetics. The combination is dangerous and is not used in any clinical setting.
• Pregnancy, breastfeeding, pediatric — Contraindicated outside formal study (the PWS adolescent program is the only authorized pediatric exposure).
• Sourcing — Tesofensine sold through "research chemical" channels has highly variable purity. Independent COA (HPLC + mass spec) is the practical floor for due diligence. Counterfeit material has been reported in multiple international markets in 2024–2025.
• Stopping — No taper is pharmacologically required; the drug self-tapers via its long half-life. Monitor cardiovascular and mood parameters for 4 weeks post-cessation.

Bloodwork & Monitoring

No formal monitoring guideline exists. The following reflects the plausible monitoring approach that mirrors the trial protocols:

• Baseline 12-lead ECG and resting heart rate / blood pressure — The most important pre-treatment assessment. Anyone with QTc prolongation, baseline tachycardia, hypertension, or arrhythmia should not initiate.
• Ongoing HR and BP monitoring — Daily home measurements during titration; clinic measurements at 4, 8, 12, and 24 weeks. Sustained HR >100 bpm or BP increases of clinical concern warrant dose reduction or discontinuation.
• CMP (comprehensive metabolic panel) — Baseline and at 12 weeks. Liver enzymes, renal function, glucose. Tesofensine is not associated with hepatotoxicity in trials but baseline establishment is prudent.
• Lipid panel — Baseline and at 24 weeks. Trial data showed no adverse lipid effect (no LDL change), but modest weight loss can produce favorable shifts.
• HbA1c and fasting glucose — Baseline and at 24 weeks. Weight loss tends to improve glycemic control; tesofensine itself has no direct insulin or glucose-modifying mechanism.
• POMS or PHQ-9 (mood screening) — Baseline and periodic. Tesofensine produces measurable mood-state shifts (increased anger/hostility, confusion at higher doses); pre-existing anxiety, depression, or bipolar history warrants formal psychiatric monitoring.
• Body composition — Beyond simple body weight. DEXA at baseline, 12 weeks, and 24 weeks gives objective fat-mass, lean-mass, and visceral fat data — important because monoaminergic appetite suppressants tend to preserve lean mass better than caloric restriction alone.
• Drug-drug check at every visit — Patients on serotonergic agents, sympathomimetics, MAO inhibitors, stimulants, or strong CYP3A4 inhibitors/inducers require dose review.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Tesofensine often also look at these:

Next Steps

Key References

1. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008 Nov 29;372(9653):1906-1913. doi: 10.1016/S0140-6736(08)61525-1. PMID: 18950853. (TIPO-1 — the foundational Phase 2b obesity trial.)
2. Greenway FL. Tesofensine — a novel potent weight loss medicine. Evaluation of: Astrup A, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss... Lancet 2008;372:1906-13. Expert Opin Investig Drugs. 2009 Jul;18(7):1023-7. PMID: 19548858.
3. Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008 Jun;16(6):1363-9. PMID: 18356831.
4. Hauser RA, Salin L, Juhel N, Konyago VL, et al. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007 Feb 15;22(3):359-365. doi: 10.1002/mds.21258.
5. Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T; ADVANS Study Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study. Arch Neurol. 2008 May;65(5):577-83. PMID: 18474731.
6. Bello NT, Zahner MR. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. Curr Opin Investig Drugs. 2009 Oct;10(10):1105-16. PMID: 19777399.
7. Sjödin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen JK, Meier D, Astrup A. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010 Nov;34(11):1634-43. doi: 10.1038/ijo.2010.87. PMID: 20479765.
8. Schoedel KA, Meier D, Chakraborty B, Manniche PM, Sellers EM. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther. 2010 Jul;88(1):69-78. doi: 10.1038/clpt.2010.67. PMID: 20520602. (Abuse-liability study — supports low scheduling risk.)
9. Appel L, Bergström M, Buus Lassen J, Långström B. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET. Eur Neuropsychopharmacol. 2014 Feb;24(2):251-61. doi: 10.1016/j.euroneuro.2013.10.007. PMID: 24239329.
10. Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of α1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010 May;35(7):1464-76. doi: 10.1038/npp.2010.16. (PMC3055463.)
11. Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A, Mikkelsen JD. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. doi: 10.1016/j.ejphar.2010.03.026.
12. Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, Lassen JB, Hansen HH. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring). 2013 May;21(5):985-92. doi: 10.1002/oby.20122. (Pharmacological rationale for Tesomet.)
13. Lehr T, Staab A, Tillmann C, Nielsen EO, Trommeshauser D, Schaefer HG, Kloft C. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol. 2008 Jan;153(1):164-74. doi: 10.1038/sj.bjp.0707539.
14. Lehr T, Staab A, Trommeshauser D, Schaefer HG, Kloft C. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine. AAPS J. 2010 Sep;12(3):117-29. doi: 10.1208/s12248-009-9164-6.
15. Huynh KD, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup AV, Feldt-Rasmussen U. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. Eur J Endocrinol. 2022 Apr 28;186(6):687-700. doi: 10.1530/EJE-21-0972. PMID: 35294397. (NCT03845075.)
16. Pérez CI, Luis-Islas J, Lopez A, Diaz-Sosa X, Pérez-Freitez K, Ruiz-Pérez L, Hattar S, Zarco N, Brito-Aquino N, Jaime-Lara R, Almanza A, Calvo-Ochoa E, Tellez LA, Gutierrez R. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PLoS One. 2024 Apr 24;19(4):e0300544. doi: 10.1371/journal.pone.0300544. PMID: 38656972. (PMC11042726 — circuit-level mechanism in lateral hypothalamus.)
17. Tsai AG. Tesofensine and weight loss. Lancet. 2009 Feb 28;373(9665):719; author reply 720. doi: 10.1016/S0140-6736(09)60432-3. PMID: 19249625.
18. Expression of concern—Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Feb 28;373(9665):719. doi: 10.1016/S0140-6736(09)60433-5. PMID: 19249626.
19. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol. 2010 May;6(5):255-69. doi: 10.1038/nrendo.2010.19. PMID: 20234354.
20. Saniona AB. Tesomet — Pipeline. saniona.com/pipeline/tesomet. Accessed April 2026. (Phase 2b PWS and hypothalamic obesity trials voluntarily paused due to funding limitations; not safety/efficacy.)
21. ClinicalTrials.gov. NCT03845075 — Randomized Controlled Trial of Tesomet in Adults With Hypothalamic Obesity. NCT03149445 — Phase 2a Tesomet in Prader-Willi Syndrome. NCT00394667 — Effect of Tesofensine on Weight Reduction in Patients With Obesity. clinicaltrials.gov.
22. FDA. Bulk Drug Substances Nominated for Use in Compounding — 503A and 503B Categories. FDA.gov. Updated 2025–2026. (Tesofensine not eligible for U.S. compounding under current bulk-substance lists.)